Image source: The Motley Fool.

Oncternal Therapeutics, Inc.(NASDAQ:ONCT)Q22021 Earnings CallAug 05, 2021, 5:00 p.m. ET

Operator

Greetings, and welcome to the Oncternal Therapeutics, Incorporated's second-quarter 2021 financial results call. [Operator instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Richard Vincent, chief financial officer. Thank you.

You may begin.

Rich Vincent -- Chief Financial Officer

Thank you, Darryl. Good afternoon, everyone, and thank you for joining us today. Joining me on this call this afternoon are our president and CEO, Dr. James Breitmeyer; and our CMO, Dr.

Salim Yazji. We welcome all of you. Today's call includes a business update, a discussion of our 2021 second-quarter financial results, as well as our upcoming milestones, which will be followed by Q&A. Today's press release and a replay of today's earnings call will be available on the investor relations section of Oncternal's website for at least the next 30 days.

We also filed our 10-Q for the second quarter of 2021 earlier today. Please note that certain information discussed on today's call is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We will be making forward-looking statements during this call about future events, such as our business and product development strategies and future financial and operating performance. Our actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with our business.

These forward-looking statements should be considered in conjunction with and are qualified by the cautionary statements contained in today's press release and our SEC filings, including our Form 10-Q for the quarter ended June 30, 2021. This conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, August 5, 2021. We undertake no obligation to revise or update any forward-looking statements to reflect events or circumstances occurring after the date of this conference call. With that, it's my pleasure to hand the call over to our CEO, Dr.

Jim Breitmeyer.

Jim Breitmeyer -- Chief Executive Officer

Thank you, Rich, and good afternoon, everyone. At Oncternal, we are committed to developing novel treatments for patients with cancer who have critical unmet medical needs. We're advancing a robust product pipeline with clinical and preclinical product candidates that target several such cancer indications. We are particularly pleased with the progress made during the second quarter of 2021 to advance the development of cirmtuzumab, our investigational, potentially first-in-class humanized monoclonal antibody that binds with high affinity to a biologically important epitope on ROR1, also known as receptor tyrosine kinase-like orphan receptor one.

Encouraging updated interim clinical trial results with cirmtuzumab plus ibrutinib in patients with mantle cell lymphoma, or MCL, and chronic lymphocytic leukemia, or CLL, were presented in a poster session at the ASCO 2021 annual meeting. In addition, in July 2021, we opened a new treatment cohort of our ongoing Phase 1/2 study to evaluate cirmtuzumab plus ibrutinib in patients with MCL who are refractory to prior BTK inhibitor treatment, including ibrutinib, acalabrutinib or zanubrutinib; and to include patients who are at high risk for progression, having had an inadequate response to ibrutinib that is only achieving stable disease or a partial response. Our CMO Salim will provide additional details on each of these. We also have an ongoing dialogue with the U.S.

FDA concerning the potential registration pathway for cirmtuzumab, and we expect further feedback on a potential pivotal study design this year. ROR1 has been an -- become an increasingly visible target in the oncology space and has been the subject of M&A activity, including the acquisition of VelosBio by Merck & Co. VLS-101, VelosBio's ROR1-targeted antibody drug conjugate, or ADC, was originally invented and developed add-on terminal, and it incorporates the cirmtuzumab antibody to target ROR1. We believe we have one of the most advanced and diverse pipelines targeting ROR1 in the industry today.

We also continue to collaborate on two investigator-sponsored clinical studies of cirmtuzumab at UC San Diego. First, a Phase 1b clinical trial of cirmtuzumab in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced unresectable breast cancer; and second, a Phase 2 clinical trial of cirmtuzumab in combination with venetoclax, a BCL2 inhibitor in patients with relapsed/refractory CLL. UCSD finished enrollment for the breast cancer study in the second quarter of this year. So moving on to our immuno-oncology cell therapy programs, we continue to make progress on our novel ROR1-targeting CAR-T and CAR-NK cell therapy candidates, moving them from the laboratory toward the clinic as planned.

We are very encouraged by the advancement of our cell therapy efforts, including successful recruitment of the internal team and external scientific advisors; preclinical activities with the Karolinska Institute in Stockholm, Sweden; development and manufacturing activities with Lentigen Technology and Miltenyi Biotech; our research collaboration with UC San Diego; and our development partnership with Shanghai Pharma Limited in Greater China. We are tremendously excited by the potential of our cell therapy program targeting ROR1, which may allow for the selective targeting of tumor cells that express ROR1 while sparing healthy tissues. We also advanced the development of TK216, our investigational targeted small molecule inhibitor of the E26 transformation specific, or ETS, family of oncoproteins. We presented encouraging interim clinical data for TK216 in patients with relapsed or refractory Ewing sarcoma in an oral session at the ASCO 2021 meeting.

Based on the data, we added an expansion cohort with an optimized dosing schedule. Salim will provide additional details on this program as well. During this past quarter, we further strengthened our executive team with two key additions in the medical and business fronts. Dr.

Salim Yazji, joining us on the call now, is our new chief medical officer. Salim brings over 25 years of experience in both industry and academic settings, leading global oncology development and regulatory strategy throughout all phases of development, including various product approvals. Pablo Urbanejaas joined us as our SVP of corporate development. Pablo is a seasoned biotech professional with a solid track record in corporate strategy and licensing, and he will lead our expanding strategy portfolio and business development functions at Oncternal.

With this, I will now turn the call over to Salim to provide more color on our clinical programs.

Salim Yazji -- Chief Medical Officer

Thank you, Jim. Good afternoon, everyone. At this year's ASCO meeting, we announced updated clinical data for cirmtuzumab in combination with ibrutinib. In patients with relapsed/refractory MCL enrolled in our ongoing Phase 1/2 trial, the data cutoff at that time was April 16.

The best objective response, complete or partial response rate, or ORR, was 83% for these heavily pretreated patients with MCL treated with cirmtuzumab plus ibrutinib, which compares favorably to historical ORR of 66% for ibrutinib monotherapy. Seven of the 18 evaluable patients, or 39%, had achieved a complete response, or CR, by chip and criteria, one of which was a complete metabolic response, CMR, by pet scan. These CRs remained durable for eight to 30-plus months. This compares favorably to the historical CR rate of 20% for ibrutinib monotherapy.

The media progression-free survival, PFS, and overall survival, OS, were not reached for MCL patients. And the PFS estimate at two years was approximately 60% with a median follow-up of 18.9 months. This compares favorably to the historical PFS of ibrutinib monotherapy of approximately 30% with a median follow-up of 24 months. For patients with CLL, the ORR was 94%, and five patients had achieved the clinical criteria for complete responses with a bone marrow confirmation pending in one patient.

The median PFS and OS has not been reached for CLL patients. And the PFS estimate at two years was approximately 82% with the median follow-up of 22.1 months. The combination of cirmtuzumab and ibrutinib continues to be well-tolerated with the safety profile consistent with or slightly improved compared to the historical data for ibrutinib monotherapy. For example, in patients with MCL Grade 3 and 4 neutrofil decrease was documented in 11.5% of the patients with cirmtuzumab plus ibrutinib, compared to 29% for ibrutinib alone from its registrational study.

We and our study investigators continue to be particularly impressed by the response in heavily pretreated patients. Six patients with MCL who has relapsed following prior autologous stem cell transplant, or CAR-T, therapy, were enrolled in our study, and all six of them responded to the combination of cirmtuzumab and ibrutinib. Four patients achieved complete response, and two patients achieved partial response. All four patients who had received prior treatment with ibrutinib responded to the treatment with cirmtuzumab and ibrutinib with the two CRs and two PRs.

We continue to support our Phase 1b investigator-initiated clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced undetectable breast cancer. At AACR in April 2021, the UC San Diego investigators presented results showing an objective response rate of 57% with an encouraging toxicity profile. These results were consistent with the previously reported interim results of the study and compared favorably to the historical results of single-agent paclitaxel, particularly for patients such as these who had received a median over six prior therapy for metastatic disease. As Jim mentioned, this trial was fully enrolled for a total of 15 evaluable patients.

The results are expected to be presented at the scientific conference or publication. Also, at AACR, we presented data from preclinical study, investigating cirmtuzumab in combination with chemotherapeutic agents, cisplatin and paclitaxel, used to treat high-grade serious ovarian cancer, HGSOC, an endometrial cell line in vitro. Cirmtuzumab demonstrated single-agent activity and enhanced the anti-corrosive effect of chemotherapeutic agents in both ovarian and endometrial cancer cell models, including platinum-resistant ovarian cancer. Our program to develop TK216, our ETS family inhibitor, continues to progress.

At this year's ASCO meeting, we presented an updated clinical data from our ongoing Phase 1/2 trial of TK216 for patients whose relapsed/refractory Ewing sarcoma, and the data cut for that was April 22. The data remains consistent and confirm and extend previous results. Two patients who achieved CR remain with no evidence of disease, one for over 24 months and the other for over 14 months on a study. The treatments continue to be well-tolerated with reversible myelosuppression as the most common side effect.

Based on our encouraging data and KOLs' feedback, in July 2021, we added a new Phase 2 expansion cohort, targeting Ewing sarcoma patients to evaluate clinical response to a single-agent TK216 using an optimized dosing regimen, treating for 28 days per cycle to intensify the amount of TK216 administered over time. I will now turn the call over to Rich Vincent to review financial results and upcoming milestones.

Rich Vincent -- Chief Financial Officer

Thank you, Salim. In October 2017, CIRM awarded an $18.3 million grant to researchers at the UC San Diego School of Medicine to advance our Phase 1/2 clinical trial, evaluating cirmtuzumab in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including MCL and CLL. We are conducting this study in collaboration with UC San Diego and expect to receive approximately $14 million in development milestones under research sub awards throughout the award period. In conjunction with this award, our grant revenue was $0.9 million for the second quarter ended June 30, 2021.

Our total operating expenses for the quarter ended June 30, 2021, were $8.6 million, including $1.8 million in noncash stock-based compensation. Research and development expenses for the quarter totaled $5.2 million. And general and administrative expenses totaled $3.4 million. Net loss for the second quarter was $7.7 million or a loss of $0.16 per share basic and diluted.

As of June 30, we had $103.7 million in cash and cash equivalents. We believe these funds will be sufficient to support our operations into 2023. As of June 30, we had 49.4 million shares of common stock outstanding. With respect to upcoming milestones for our cirmtuzumab program, we expect an interim clinical data update for the ongoing Phase 1/2 study in MCL and CLL at a scientific conference in the fourth quarter of 2021, a clinical data update from the fully enrolled ongoing breast cancer Phase 1b IST study, an FDA interaction update regarding a potential registration trial of cirmtuzumab in patients with MCL and further preclinical data in additional ROR1-expressing tumors.

On the cell therapies front, we are advancing our ROR1 CAR-T program to treat the first patient in the first half of 2022. For our TK216 program, we expect an interim clinical data update for the ongoing Phase 1/2 expansion cohort in Ewing sarcoma at a scientific conference in the fourth quarter of 2021, as well as additional preclinical data and other ETS-driven tumors. Now I will turn the call back over to Jim.

Jim Breitmeyer -- Chief Executive Officer

Thank you, Rich. In closing, this past quarter, we presented very encouraging data from our clinical programs. We've strengthened our management team, and we continue to have a strong balance sheet and look forward to multiple potential catalysts in the coming months. Thank you for listening to our presentation today.

With that, I'll turn things back to Darryl for the Q&A portion of this afternoon's call.

Operator

Thank you. [Operator instructions] Our first questions come from the line of Hartaj Singh with Oppenheimer. Please proceed with your questions.

Hartaj Singh -- Oppenheimer & Co. Inc. -- Analyst

Great. Thank you, and thanks for the presentations, gentlemen. Jim, a couple of questions. One is, you sort of talked about earlier or about the potential registrational trial for cirmtuzumab and ibrutinib in MCL.

Could you talk a little bit more about what the comp tours of that could look like, whether it would be in a proper Phase 3 drug trial, Phase 2 number of patients? How large could it be? I know you might not have the full information now, but if you can just sort of give us an idea. And then, in your CAR -- your ROR1 CAR-T program, can you talk a little bit about how do you expect to undertake the manufacturing of that for your patients as you dose them? Will it be sort of localized manufacturing at the various facilities where you're giving the CAR-T? Will it be more centralized manufacturing? And then, I got a quick follow-up. Thank you.

Jim Breitmeyer -- Chief Executive Officer

Thank you for your questions, Hartaj. So your first question regards a potential pivotal trial that we are actively discussing with the FDA. And as I said, we are hopeful that we may reach agreement on a study design during this calendar year. So certain elements are still being discussed.

But with both based on FDA feedback and discussions with KOLs and considering commercial considerations, we do believe that a randomized trial of cirmtuzumab plus ibrutinib versus ibrutinib is by far the most robust and best way to go forward toward approval. We have -- we are also carefully examining the ibrutinib response into -- for patients with MCL. And we believe that there is unmet medical need there where we could have a population of MCL patients that is more likely to progress on ibrutinib, without, we think, having a dramatic reduction in the patient population for eventual commercial rollout. And then, I'd say that we're still -- the statistics are still being discussed with FDA.

But for -- as you can imagine, for a randomized trial, it would probably be in the range of several hundred patients, let's say, low single-digit hundreds of patients, while we work out the particulars. So as far as CAR-T manufacturing is concerned, we have -- as I mentioned, we're working with Miltenyi, and they are developing a very interesting technology that would permit local and regional processing of the cells. And we are looking at, for example, the Miltenyi prodigy system, which is a closed bench-top system where many of the steps to process the T-cells from the patient can be done in a fairly common GMP facility, not requiring brick-and-mortar. So that is -- that's a leading example of what we're considering on the manufacturing side, so that we can do the processing near where the patient will be located.

Hartaj Singh -- Oppenheimer & Co. Inc. -- Analyst

Great, great. Thank you, Jim. And then just a quick question on the preclinical data that you're going to present in the fourth quarter of additional ROR1-expressing tumors. Is that in the solid tumor domain, liquid tumor domain? Or does -- and will you be looking combo or monotherapy there? And thank you for the questions.

Jim Breitmeyer -- Chief Executive Officer

Certainly, Hartaj. So what we -- with our -- with Pablo Urbanejaas joining of the company and his strength in strategic planning, we are doing an extensive review of a number of indications where literature or existing preclinical data suggest that ROR1 inhibition could be clinically meaningful. And it is including both solid and liquid tumors, and it's including both monotherapy and combination therapies. And so with that, we're going to put each of those indications through the ringer pressure test and determine what makes the most sense to proceed with for our upcoming clinical indication or indications.

Hartaj Singh -- Oppenheimer & Co. Inc. -- Analyst

Great, great. Thank you, Jim. I'll get back in the queue.

Jim Breitmeyer -- Chief Executive Officer

Thank you, Hartaj.

Operator

Thank you. Our next questions come from the line of Robert Burns with H.C. Wainwright. Please proceed with your questions.

Robert Burns -- H.C. Wainwright & Co. -- Analyst

Hey, guys, thanks for taking my questions, and congrats on the quarter. Just two for me, if I may. First, you have framed expectations with regard to the update we're expected to see in 4Q for cirmtuzumab plus ibrutinib in MCL. In particular, what the duration of follow-up will look like there? And any incremental data we may see? And then, my second question is, considering the data we've seen within the Phase 1 breast cancer study and now that it's fully enrolled, can you discuss your current thoughts around next steps within breast cancer? Or if you're planning on pivoting to a different indication within the solid tumor space? Thank you.

Jim Breitmeyer -- Chief Executive Officer

Thanks for the question, Rob. I'll answer the second one first and then turn over to Salim for the first one. So breast cancer is going to be one of -- probably at this point, first among several indications that we're looking at in this strategic planning process. And so we are -- we really like the breast cancer results, and they're very encouraging, apparently, double the objective responses compared to paclitaxel alone with a good safety profile.

So that is -- that's certainly something that we'll think hard about building on. So let me turn it over to Salim as far as how much follow-up and what we may be presenting in our next interim update.

Salim Yazji -- Chief Medical Officer

Yes. Thank you, Jim. Actually, I mean, what's gonna happen is we most likely gonna present the data at the next scientific conference. And as you know, we only can present the evaluable patients.

They have to have at least one evaluation after two months of treatment. So we would expect probably a handful of patients, additional patients to be presented at the end of the quarter. As you know now, we only have 18 evaluable patients for MCL and 34 evaluable patients for CLL. So for CLL, we're not gonna have any more patients, but we will have 18 evaluable operations, more than 18 evaluable patients by the end of the quarter.

Robert Burns -- H.C. Wainwright & Co. -- Analyst

Awesome. Thanks for the color there, guys.

Jim Breitmeyer -- Chief Executive Officer

Sure. Thank you, Rob.

Operator

Thank you. Our next questions come from the line of Carl Byrnes with Northland Securities. Please proceed with your questions.

Carl Byrnes -- Northland Securities -- Analyst

Great, thank you, and congratulations on all the progress. Obviously, a number of conferences toward the end of the year, ASH in December, the San Antonio Breast Cancer Symposium also, I believe, in early December and then the CTOS symposium in November. Would you anticipate any presentations prior to those events? And if so, what events might they be? Thanks.

Jim Breitmeyer -- Chief Executive Officer

Thank you, Carl. And you did name the most likely venues for us to present in the fourth quarter. We've presented before their high profile, their great conferences. At this point, we don't have anything before that on the books.

But we always keep our eyes open for opportunities to try to give updates when we can.

Carl Byrnes -- Northland Securities -- Analyst

Great, thanks. That's helpful. And also, looking back to cirmtuzumab for MCL with respect to registrational trial, just kind of assuming for the moment that the PFS number that we find is very high, what might be done in terms of a trial design that wouldn't penalize you, if you will, for having a long PFS? In other words, if we want to accelerate something to market and you've got obviously PFS, progression free survival of two times, what could be done there? Thanks.

Jim Breitmeyer -- Chief Executive Officer

Yes. So great question, Carl. And so what we think is particularly interesting is that we've got a strong objective response rate, and that is an endpoint that has been accepted by the FDA previously for accelerated approval. And then, we have this substantial improvement in progression-free survival, which is an endpoint that has been accepted for full approvals.

And so we're considering that certain patients with MCL on ibrutinib have a shorter progression-free survival than average. And so we may be able to further accentuate the difference in PFS by enrolling a population of MCL patients with unmet medical need.

Carl Byrnes -- Northland Securities -- Analyst

And then, would you also potentially be able to follow that up with kind of a post surveillance for other patient populations to achieve kind of a more reflective PFS?

Jim Breitmeyer -- Chief Executive Officer

Yes. The short answer is yes.

Carl Byrnes -- Northland Securities -- Analyst

Cool. Great. Thanks so much. That's helpful.

Jim Breitmeyer -- Chief Executive Officer

Thank you, Carl.

Operator

Thank you. [Operator instructions] Our next questions come from the line of Kumar Raja with Brookline Capital Markets. Please proceed with your questions.

Kumar Raja -- Brookline Capital Markets -- Analyst

Thanks for taking my questions. With regard to the breast cancer trial, what do we know about the ROR1 expression in the patients who had a partial response? And also, how does the treatment impact their ROR1 expression?

Jim Breitmeyer -- Chief Executive Officer

Salim?

Salim Yazji -- Chief Medical Officer

Yeah, so you're talking about the expression of ROR1 and tumor type? Just to clarify the question.

Kumar Raja -- Brookline Capital Markets -- Analyst

Yeah, I understand that in the breast cancer trial, all of them had ROR1 expression based on IHC. My question is like, is there a cutoff point where you're seeing the partial responses and whether this can be optimized in a future trial, so that you are selective for patients whom you think would be responsive?

Salim Yazji -- Chief Medical Officer

Excerpt from:
Oncternal Therapeutics, Inc. (ONCT) Q2 2021 Earnings Call Transcript - Motley Fool

The adorable Cavalier King Charles mix puppy is acting very unpuppy-like: He is lethargic and doesn't have an appetite.

Veterinary technician Carlene Ternes holds the tiny, white-and-ginger puppy up into the air and gazes at his fuzzy, teddy-bear face.

Hes not eating, but his tail works, she reports, grinning.

Logan is just one of the many patients spending Friday night at the Red River Animal Emergency Hospital and Referral Center. The 24/7 emergency veterinary hospital the only one in North Dakota or western Minnesota treated somewhere between 18,000 and 20,000 patients last year, according to Dr. Andy Carver, the hospital's director and the first board-certified specialist in emergency and critical care in North Dakota.

In fact, the 11,000-square-foot hospital is so busy that plans are underway to add a $6 million, 17,000-square-foot addition to the building at 4491 23rd Ave. S., Fargo. The hospital will also add 20 staff, including specialists in internal medicine, oncology and surgery as well as critical care veterinary technicians, says Bill Walker, hospital administrator. A groundbreaking to commemorate the new construction will be held at 1 p.m., Thursday at the hospital.

As a pet owner who has brought my own dogs into the ER several times, I've often wondered what goes on behind closed doors at an emergency veterinary hospital. Now, thanks to access granted by Carver and Bill Walker, the hospital administrator for the RRAEHCC, I know.

Within four hours there, I was exhausted. In that time, I saw dozens of animals, including a ferret named Bandit who ingested an Advil, a green conure with fluid build-up in its abdomen and a very large dog named Elvis who jumped out of a moving car.

I also saw a bunch of hard-working vets and supporting staff who impressed me with their professionalism, teamwork and stamina.

Veterinary staff Alex Wong (left) and Amanda Fish remove the oxygen tube from a Basset hound's nose as they prepare him to go home. / By Tammy Swift

I can't stop comparing the facility to a human hospital.

There's a posh waiting room, a big reception desk and a slew of exam rooms.

The waiting room of the Red River Animal Emergency Hospital was empty most of last year when COVID-19 made it impossible for owners to wait for their pets as they were treated. As in many other veterinary clinics, owners needed to wait in their cars until their pets could go home. / By Tammy Swift

In the back, there's a glass-enclosed recovery unit and ICU units outfitted with oxygen and temperature control. There's a triage area, a blood bank, operating rooms, an x-ray room and a room that contains a human-grade CT scanner. RRAEHCC even has a mechanical ventilator.

The hospital has several pieces of human-grade medical equipment, including this CT scanner. Tammy Swift / The Forum

Carlene Ternes was instrumental in setting up the hospital's blood bank, which is now regularly restocked by more than 30 dogs and 15 cats. The pets receive treats and toys for their life-giving gift. / By Tammy Swift

Vet techs like Ternes marvel over how much the hospital has grown in her nine years here. When she started, the clinic was in a single suite on Oak Manor Drive South. In the early days, only one or two vet techs would work each night and there would be evenings when no patients were admitted.

In 2018, the hospital moved into the site of the former Golden Corral. Their new space can accommodate up to 38 animals at once and it frequently does. So much so that they have had to initiate a priority system. Once the hospital reaches Level 3 capacity, they will only accept the most critical cases. Owners whose animals have a less-serious ailment, such as an ear infection, are encouraged to monitor their pets closely and get them to their primary providers as soon as possible.

Vet tech Kailley Martinson holds a cat still while Molly Moritz draws a blood sample from its jugular vein, a commonly used venipuncture site for felines. / By Tammy Swift

Talk to staff and they share many theories as to the hospital's popularity. Carver attributes it to a growing regional awareness that the facility exists. Walker attributes it to the RRAEHRC's excellent reputation. Still others link it to the metro area's vigorous growth.

Another factor: People nowadays are more willing to pamper their pets. "More people are willing to spend money. They're family members now," Ternes says.

Carver says he hates turning owners away, as he knows how upsetting it is when one's pet suddenly gets sick. Even so, it has become necessary in a facility with limited room and staff. "I think its tough for people to realize the whole art and science behind needing to triage things and prioritize care," he says. "Everyone who comes there truly feels its an emergency. They see a quiet parking lot or lobby and get frustrated. I wish they understood ... priority has to be on caring for the sickest ones. We're not just being lazy and hanging around behind closed doors."

Just as I arrive, Carver emerges from surgery. Hes just operated on a 7-pound Yorkie to remove foreign objects from the puppys stomach.

The dogs owner brought him in after noticing the little guy was shaky and uncomfortable.

Carver soon found the problem. Or, actually, a whole wad of problems. The dog had ingested enough hair ties to outfit a drill team.

Carver removed a wad as big as a newborn's fist, along with another oddity a single jalapeo.

Any veterinary surgeon worth their scalpel has found a grab bag of goodies in the digestive systems of pets, from rocks, pantyhose and socks to children's toys, pacifiers, tinsel and pencil erasers.

While a "dog eat sock" world might sometime be caused by a nutritional deficiency or anxiety, Carver says most cases stem from pets being playful and inquisitive. "They're curious about things and they may like the mouth-feel and, without thinking about it, they may wind up swallowing it," he says.

Carver moves on to perform an ultrasound on a small dog.

The source of the dogs pain is soon apparent. A healthy pancreas is less than one centimeter thick and is hard to find on an ultrasound, Carver says. But this dogs pancreas is a billowy mass, filling the upper one-fourth of the ultrasound screen.

Dr. Andy Carver (left) performs an ultrasound on a dog with pancreatitis, while Dr. Anna Stansbery assists.

The little guy has a taste for eating trash, which explains the pancreatitis, Carver says. The pancreas produces enzymes to assist in food digestion and hormones to regulate blood sugar or glucose metabolism. When it isn't working right, it activates those enzymes prematurely, so they actually start digesting the pancreas itself.

Some bouts of pancreatitis are mild and can be treated at home. But some cases are severe and life-threatening; those animals may wind up in ICU, hooked up to feeding tubes and treated for multiple related problems.

Carver says this dog's pancreatitis is in the "moderate severity" range. The dog will make it, but his garbage-foraging days are over.

The ultrasound has helped RRAEHRC staff diagnose problems with greater efficiency and accuracy, Carver says. Before they had the machine, they relied on a patients bloodwork, which would have shown elevated liver enzymes. It could have easily been misdiagnosed as liver disease. This way, the pup will be on the road to recovery much more quickly and his owners will not have to spend more time and money trying to get to the real problem.

When people are looking for highly specialized medical care, many will travel to Mayo Clinic in Rochester, Minn. But when Mayo physicians and Minneapolis-area pet owners seek highly specialized care for their pets, many will travel to Fargo.

Dr. Ashlyn Kuklock performs emergency surgery on a canine patient while Kailley Martinson (center) and Rachel Manning assist. / By Tammy Swift

As the RRAEHRC has the only dialysis machine for animals between Seattle and Chicago, the University of Minnesota Veterinary Hospital routinely refers dogs and cats with failing kidneys here.

A recent example: After a referral from the University of Minnesota, Carver and Dr. Sam Wigglesworth, the second criticalist to join the RRAEHCC staff, performed a therapeutic plasma exchange on a golden doodle, who had managed to eat an entire bottle of ibuprofen.

The animal was in acute kidney failure, so the two vets performed a therapeutic plasma exchange, a process in which they used dialysis to separate the cells from the liquid part of the blood, then discarded the liquid part, which contained the toxins. They then replaced that fluid with donor fluids.

"The dog did great and went home with no symptoms," Carver says.

In another case, a Mayo doctor's dog, Ezra, was on dialysis at the Fargo hospital for weeks, Walker says. A little later, the hospital again received a call asking if they could keep Ezra for 10 days. Staffers were alarmed: Was Ezra sick again? Oh no, the doctor responded. He planned to go on vacation and didn't trust anyone else to watch his dog.

One of the more serious cases of the day involved a farm dog hit by a car. Tex's owner had driven two-and-a-half hours from Devils Lake to bring him here. She heard this is the best place, says Dr. Anna Stansbery, who is overseeing his case.

Veterinary technician Shelby Feickert comforts Tex, a cattle dog who suffered a severe compound fracture after being hit by a vehicle. / By Tammy Swift

Tex is a handsome Australian shepherd with long, russet hair. His snout is enclosed in a muzzle and his breathing is shallow and fast. His amber eyes are wide open, but dont seem to focus on anything. He is pretty shocky, a vet tech remarks.

Upon seeing his injury, its easy to see why. Tex's left front leg is broken so badly that splinters of bone peek through the skin. The limb bends at an unsettling angle.

Pain relief is first priority. While several techs stroke to calm him, Stansbery calls for a shot of methadone a quick, effective painkiller for animals.

With Tex's pain managed, Stansbery analyzes the best way to proceed. The owner could take the dog to the University of Minnesota Veterinary Medical Center, where they could perform a complex surgery in attempts to reconstruct the leg. But it would cost at least $5,000 and contain no guarantee that the leg would work.

Tex is 12 years old. Most dogs adapt well to three-legged life, especially smart, athletic herding dogs, Stansbery explains. At the same time, the loss of a front limb is harder, as the front legs bear more weight than the hind legs.

She discusses the options with the owner, who decides it is best to amputate.

When Tex awakes, he will be a three-legged dog. But, as Stansbery points out, our pets don't wrestle with the same pangs of self-pity that we do.

"They don't wake up and say, 'Poor me,'" Stansbery says. "It's more like, 'What can I pee on and what's for dinner?'"

Even in this adrenaline-charged atmosphere, I spot many little acts of compassion.

Sarah DeCrans and her French bulldog, Nigel, provide a morale-boosting visit to vet tech Chris Knutson. / By Tammy Swift

One chihuahua has been crying most of the night. A veterinary assistant walks over and strokes its tiny nose, which immediately calms the dog. Later, I see another vet assistant cuddle a tiny calico kitten simply because "he's so darned cute."

A veterinary assistant reaches into the kennel of an ailing Chihuahua to comfort her by stroking her nose. Tammy Swift / The Forum

This tiny calico kitten looks particularly tiny and vulnerable in his kennel, but is comforted by piles of blankets and the snuggles of veterinary staff. / By Tammy Swift

Out in the triage area, another puppy is having a bad day. Freia is a baby black lab who had a run-in with a lawn mower. Its one of the trials of puppyhood: Learning how to co-exist amid all the shiny, cleverly-hidden dangers in the human world.

Dr. Ashlyn Kuklock carefully examines the afflicted foot to make sure Freia only has soft-tissue damage. But first, she caves to the pup's sweet charm, cradling the little Lab's head in her hands to plant a masked kiss to Freias soft, furry forehead. The puppys tail whips back and forth hopefully.

Experienced vet tech Carlene Ternes knows one of the perks of the job is the ability to snuggle and comfort adorable pets like Logan, a puppy admitted for lethargy and poor appetite. / By Tammy Swift

Its a testimony to puppy optimism that even when they hurt, most still find a reason to wag their tails.

In a quiet area on the south end of the treatment area, a lone veterinary technician works over a gray cat. I'm about to ask what he's in for before realizing he has been euthanized. She is cutting off the bandage that secured his IV; theres no need for that now. Black ink prints of his paws have been made on white cards and rest by his body. He lies atop a cuddly fleece blanket. For some reason, I am glad for the blanket, this last offering of comfort before he crossed the rainbow bridge.

Emergency pet hospitals often must perform euthanizations when an animal becomes gravely ill or critically injured outside of their regular veterinarian's office hours. Grieving owners are able to say goodbye to their pets and grieve in the privacy of a special "comfort room," which features overstuffed furniture and displays this comforting passage from "The Rainbow Bridge." Tammy Swift / The Forum

It is a sad, quiet moment.

Its a question I ask several people who work there. How can these animal-loving professionals handle the euthanizations? Their answers reflect a combination of professional reserve and compassion. They tell me that it is easier for them to remain objective than it is for a grief-stricken owner. They also talk of mercy, how they see this as a way to relieve an animal whose body is racked by pain, severe illness or the ravages of old age.

But after saying all this, a couple of vet techs admit it is the least favorite part of their job.

This tiny calico kitten looks particularly tiny and vulnerable in his kennel, but is comforted by piles of blankets and the snuggles of veterinary staff. / By Tammy Swift

Walker says the team likes to focus on the the triumphs the dog that beat life-threatening sickness, the kitten saved by dialysis. "Compassion fatigue is very real in the veterinary business," he says. "So it's the good things, the ones that survive and beat the odds, that keep everyone going."

All of the veterinary staff are pet lovers, as illustrated by veterinary assistant Rachel Manning's "cat-too" of her two cats. / By Tammy Swift

See more here:
From broken legs to a punky pancreas, here's what a night in Fargo's animal ER is like - INFORUM

This one will get you right in the feels. And it's going to hurt.

Stories like this work the emotions in two ways. They anger you and break your heart.

Who could have done such a thing and why? You're hoping it was just an accident and that way you can just have pity on this poor pup for an unfortunate and unlucky accident. We're still hoping that's the case.

But it feels like this could be more and worse. An act of just pure disregard. Who would throw a dog in a dumpster and leave them there. Were they hoping something like this would happen to the animal? If they put the dog in the trash, they had to of known something like this could happen.

We've got lots of questions and CAHS is hoping you can shed some light on the situation.

Please take a look at the dog in the picture above. Share the Facebook post, picture, and phone number.

Check back often to see if Capital Area Humane Society has updated the information.

If you have any information regarding this dog, please contact CAHS at (517) 626-6060.

From what you can read in the Facebook post, she was in a dumpster and it appears that she was subsequently dumped into the back of a garbage truck.

She sustained life-threatening injuries, and is lucky to be alive. She is currently at an emergency veterinary clinic receiving the care she needs. (CAHS)

If you can, help us find out what happened and if someone did this.

To prepare yourself for a potential incident, always keep your vet's phone number handy, along with an after-hours clinic you can call in an emergency. The ASPCA Animal Poison Control Center also has a hotline you can call at (888) 426-4435 for advice.

Even with all of these resources, however, the best cure for food poisoning is preventing it in the first place. To give you an idea of what human foods can be dangerous, Stacker has put together a slideshow of 30 common foods to avoid. Take a look to see if there are any that surprise you.

LOOK: The least obedient dog breeds

MORE: Unique Pets You Can Legally Own In Michigan

MORE: Thanks for Adopting from the Capital Area Humane Society

Go here to see the original:
Help Us Find Out Who Did This Horrible Act of Animal Cruelty - wjimam.com

Joe will be there to greet you with a lot of love and affection, that's why we all need a Joe in our life.

Joe is a Shepherd and Britney Spaniel mix that is a pretty sweet boy who is currently living at the Humane Society's Pets Fur People in Tyler. Joe is three years old, weighs about sixty pounds and he's been neutered, is current on starting vaccinations, including rabies, and has been microchipped for identification purposes. Pets Fur People's Executive Director Gayle Helms says Joe would thrive in a family with children and would be perfect for a family that already has dogs and or cats. He can be in inside dog too because he's been house trained. Like all adoptees, Joe will go home with a starter kit of food, a collar and leash and a certificate for half price on basic obedience training from Tyler Obedience Training Club.

For additional information on adopting Ally call 903.597.2471 or check the Humane Societys Pets Fur People website. Due to concerns over COVID-19, pet adoptions are currently being handled by appointments only. Check out the animals that are available for adoption. Adoption hours are Tuesday through Saturday 10 a.m. until 5 p.m. - closed for lunch 1 - 2 p.m. The Humane Societys Pets Fur People is the oldest brick and mortar no kill shelter in East Texas. Pets Fur People offers dog boarding and routine vaccinations, except for rabies, to the public for dogs and cats. Follow them on Facebook, Twitter and Instagram. Please be a responsible pet owner - spay or neuter your pets. Donations are appreciated.

To prepare yourself for a potential incident, always keep your vet's phone number handy, along with an after-hours clinic you can call in an emergency. The ASPCA Animal Poison Control Center also has a hotline you can call at (888) 426-4435 for advice.

Even with all of these resources, however, the best cure for food poisoning is preventing it in the first place. To give you an idea of what human foods can be dangerous, Stacker has put together a slideshow of 30 common foods to avoid. Take a look to see if there are any that surprise you.

Why do they meow? Why do they nap so much? Why do they have whiskers? Cats, and their undeniably adorable babies known as kittens, are mysterious creatures. Their larger relatives, after all, are some of the most mystical and lethal animals on the planet. Many questions related to domestic felines, however, have perfectly logical answers. Heres a look at some of the most common questions related to kittens and cats, and the answers cat lovers are looking for.

To prepare yourself for a potential incident, always keep your vet's phone number handy, along with an after-hours clinic you can call in an emergency. The ASPCA Animal Poison Control Center also has a hotline you can call at (888) 426-4435 for advice.

Even with all of these resources, however, the best cure for food poisoning is preventing it in the first place. To give you an idea of what human foods can be dangerous, Stacker has put together a slideshow of 30 common foods to avoid. Take a look to see if there are any that surprise you.

From grazing Tibetan antelope to migrating monarch butterflies, these 50 photos of wildlife around the world capture the staggering grace of the animal kingdom. The forthcoming gallery runs sequentially from air to land to water, and focuses on birds, land mammals, aquatic life, and insects as they work in pairs or groups, or sometimes all on their own.

Read the original here:
Everyone Needs A Joe In Their Life - mix931fm.com

In the midst of media events across the country, the college football landscape was shaken up by a monster rumor byBrent Zwerneman of the Houston Chronicle.

According to the article that cited unnamed sources, both Texas and Oklahoma have "reached out to the [SEC] about potentially joining." The article also mentions that the decision to add the Sooners and Longhorns to a potential 14-member SEC could come "within a couple of weeks."

Nine years ago, Texas A&M and Missouri left the Big 12 for the SEC. It was almost a decade ago since Colorado left for the Pac-12 along with Nebraska bolting for the Big Ten.

This is a move that could significantly hurt the Big 12 and open up a whole new can of worms on realignment. When you consider the lucrative TV deal that could be in place with the SEC, it makes a ton of sense.

The reaction afterward was insanity all over social media. In fact, schools involved already started giving statements to media members.

Can you imagine Texas regularly playing Alabama in college football? Or, imagine Oklahoma battling some of the SEC powers andtrying to punch their ticket College Football Playoff in this competitive conference? Finallyimagine if these rumors are stumped by a jealous Texas A&M that doesn't want to share their space in the SEC with neighboring universities.

We will soon find out if these fantasies and rumors will become a reality.

EP Animal Services Adoptable Dogs

To prepare yourself for a potential incident, always keep your vet's phone number handy, along with an after-hours clinic you can call in an emergency. The ASPCA Animal Poison Control Center also has a hotline you can call at (888) 426-4435 for advice.

Even with all of these resources, however, the best cure for food poisoning is preventing it in the first place. To give you an idea of what human foods can be dangerous, Stacker has put together a slideshow of 30 common foods to avoid. Take a look to see if there are any that surprise you.

See more here:
Could Texas & Oklahoma Make a Move to the SEC? It Looks Possible - krod.com

On Saturday, November 30, 2019, as the Great Danes finished defeating Central Connecticut by a score of 42-14 in the NCAA playoffs at Tom & Mary Casey Stadium, I am positive that Greg Gattuso did not think that it would be the last time for nearly two years that he would see fans in the UAlbany home stands. Well, that has all changed. Today the University at Albany announced that they will "open all of its athletic venues at full capacity this fall in line with updated guidance from the CDC and New York State."

According to the press release sent out by the Great Danes Athletic Department this afternoon, "After more than a year, we are thrilled to invite fans back to our competitions and other events at full capacity," said UAlbany Director of Athletics Mark Benson. "Our Great Dane student-athletes thrive on fan support. We cannot wait to see our fans tailgating in the parking lot and hear them cheer on their Great Danes as they run into Casey Stadium through a cloud of purple smoke. It has been too long, and we are excited to welcome the Capital Region back to campus."

Benson joined The Drive with Charlie & Dan this afternoon. His enthusiasm was obvious and though he is excited for students to come to games and for student athletes to have the opportunity to play in front of their family and friends, the opportunity to generate revenue is just as exciting. Most Division I athletic programs count on their home contests, especially in football and basketball, to generate much needed funds. Ticket sales, corporate advertising and alumni donations are all tied to live sporting events. Mark Benson knows the value of live events and the importance of getting supporters on campus.

The Great Danes Football team plays their first home game of the season on September 11th at 7pm. It will be their "Hometown Heroes" game. To find out how you can donate tickets to healthcare workers, first responders and military personnel, go to http://www.ualbanysports.com. It will be fun to see the crowd cheer again at Tom & Mary Casey Stadium.

To prepare yourself for a potential incident, always keep your vet's phone number handy, along with an after-hours clinic you can call in an emergency. The ASPCA Animal Poison Control Center also has a hotline you can call at (888) 426-4435 for advice.

Even with all of these resources, however, the best cure for food poisoning is preventing it in the first place. To give you an idea of what human foods can be dangerous, Stacker has put together a slideshow of 30 common foods to avoid. Take a look to see if there are any that surprise you.

Read more:
UAlbany Football Ready to Welcome Fans Back - WTMM 104.5 The Team - ESPN Radio

Previously announced Texas Gubernatorial candidate Don Huffines will be appearing today (July 22nd) in Wichita Falls.

Huffines, a former Texas state senator, is one of four Republicans who have announced their candidacies in next year's GOP primary.

The Don Huffines Meet & Greet with supporters will be held from 5:30pm-7pm at The Forum, located at 2120 Speedway Avenue, Wichita Falls, TX 76308.

Earlier this week, Huffines appeared onThe Chad Hasty Show to discuss his campaign.Heblamed Governor Greg Abbott and his "failed leadership" for the special session that is currently going on in Austin.

This is another example of failed leadership by our Governor. He's allowed this to happen. During the regular session as you recall right there at the end he had his election integrity bill up and they (Democrats) fled. They couldn't get the bill out because they broke quorum. You know what his response was to that? He signed over 300 Democrat bills into law. Then he approved their budget that they all voted for. I mean, who would have done that? He lost all the leverage that he had.

Lubbocks Epic $2 Million Dollar Home Has an Indoor Basketball Court

To prepare yourself for a potential incident, always keep your vet's phone number handy, along with an after-hours clinic you can call in an emergency. The ASPCA Animal Poison Control Center also has a hotline you can call at (888) 426-4435 for advice.

Even with all of these resources, however, the best cure for food poisoning is preventing it in the first place. To give you an idea of what human foods can be dangerous, Stacker has put together a slideshow of 30 common foods to avoid. Take a look to see if there are any that surprise you.

Originally posted here:
Don Huffines Appearing Today at The Forum in Wichita Falls - News/Talk 790 KFYO

Every Wednesday at 8:30we're joined by John Perreault, Executive Director of theBerkshire Humane Societyto discuss all the happenings at their Barker Road facility, plus talk about their Pet of the Week.

This week's Pet of the Week is Charlie a 2-year old male boxer/lab mix who loves to go for rides in the car, play fetch, and walk outdoors. Hes a bit shy and jumpy when meeting new people, so a home without small children would be best for him.Thevolunteers and staff at Berkshire Humane are working with him to help him overcome his fears and gain confidence. He should not live with other dogs or cats as he did not get along with a dog in his previous home and he has a high prey drive. After a good play session or hike, Charlie is content to go inside and relax. Please call the Berkshire Humane Society kennel at 413-447-7878, extension 126 if you are interested in Charlie.

TheBerkshire Humane Society is now back open to the public for regular hours.

To prepare yourself for a potential incident, always keep your vet's phone number handy, along with an after-hours clinic you can call in an emergency. The ASPCA Animal Poison Control Center also has a hotline you can call at (888) 426-4435 for advice.

Even with all of these resources, however, the best cure for food poisoning is preventing it in the first place. To give you an idea of what human foods can be dangerous, Stacker has put together a slideshow of 30 common foods to avoid. Take a look to see if there are any that surprise you.

Why do they meow? Why do they nap so much? Why do they have whiskers? Cats, and their undeniably adorable babies known as kittens, are mysterious creatures. Their larger relatives, after all, are some of the most mystical and lethal animals on the planet. Many questions related to domestic felines, however, have perfectly logical answers. Heres a look at some of the most common questions related to kittens and cats, and the answers cat lovers are looking for.

Go here to read the rest:
Berkshire Humane Society Pet of the Week: Meet Charlie - Live 95.9

Curiosity killed the cat, but the biggest danger to a beloved pet could in fact be the seemingly benign plants lurking in a home.

Most cats are fastidious creatures, and because they tend to be careful about what they eat, poisoning is generally rare, according to the International Cat Care Organization.

However, to be on the safe side, here is a list of the most common plants toxic to cats to avoid growing in your home or garden.

Lily toxicity is particularly dangerous for cats and can result in death. The entire lily plant is toxic: from the stem to the flowers, leaves, bulb, pollen and even the water in the vase, warns American Kennel Club Chief Veterinary expert, Dr. Jerry Klein.

"Signs may start with drooling and vomiting, painful abdomen, abnormal heart rates but can lead to serious complete urine shutdown production, which is usually fatal, within 48 hours," Klein told Newsweek.

Consumption most commonly occurs when pollen that has fallen from the plant is licked off the cat's fur during grooming, according to U.K. charity Cats Protection.

Klein concurred, explaining that flower arrangements are the most common cause of lily exposure to cats.

"Every part of the lily is extremely dangerous for cats," cat behavior expert and author Pam Johnson-Bennett told Newsweek. "Even coming in contact with the pollen can cause acute kidney injury."

There are many varieties of lilies, but the most dangerous and potentially fatal are true lilies. These include tiger, day, Asiatic, Easter and Japanese show lilies.

These colorful flowers are harmful to many petsmainly because of their bulbs, which are toxic if ingested.

"These plants usually contain specific toxins throughout the plant (glycosides), but the compounds tend to have much more concentrated alkaloids in the bulb," Klein told Newsweek.

"Glycoside toxicity is usually exhibited with gastrointestinal signs such as drooling, vomiting and diarrhea but can range to neurologic and cardiac changes in extreme cases."

Tulips and hyacinths also contain the alkaloid Tuliposide A, Klein added.

As the bulbs are more commonly dug up by curious dogs in the back garden, these flowers usually pose less of a risk to pet cats.

This popular ornamental garden plant is considered to be toxic to cats as it contains cardiac glycosidesorganic compounds that have the potential to cause gastrointestinal tract irritation, abnormal heart function, hypothermia and even death.

Cardiac glycosides inhibit the sodium/potassium pump in cells, causing hyperkalemia (high potassium) and increasing intracellular calcium, which can lead to cardiac irritability and arrhythmias, according to the ASPCA Animal Poison Control Center. Glycosides also decrease sympathetic tone and increase vagal tone, resulting in bradycardia (slow heart rate) and heart block.

Symptoms to look out for include vomiting, diarrhea, bradycardia or tachycardia (fast heart rate), blood pressure changes or lethargy.

These pretty plants contain colchicine, which is extremely toxic to cats. It can cause multiple organ damage such as kidney and liver damage, severe and bloody vomiting, diarrhea and respiratory failure, the ASPCA notes.

Symptoms might be delayed for several days, so it is important to seek veterinary attention if you suspect your cat has ingested the plant.

The iris can cause tissue irritation when consumed or come into contact with. Ingestion can result in drooling, vomiting, diarrhea and lethargy, according to the Pet Poison helpline.

This houseplant is found in many homes and offices. Despite its name, it is not actually in the Liliaceae family.

"Peace Lilies contain calcium oxalate crystals which cause burning and irritation of the mucous membranes of the mouth, the esophagus and the stomach leading to salivation, vomiting, diarrhea," Klein told Newsweek.

Signs of toxicity include burning and irritation of the mouth, tongue and lips, excessive drooling, vomiting and trouble swallowing.

The entire genus of this plant species is extremely dangerous to most pets, including cats. Eating even a few leaves can cause vomiting, diarrhea, drooling, paralysis, shock, coma and death, the American Kennel Club warns.

"Azaleas and Rhododendrons contain a neurotoxin called Grayantonin, a toxin that affects the body's sodium channels which can then affect muscle tissue of the heart and skeletal muscles," Klein told Newsweek. "All parts of the plant can be toxic and even small ingestions of the plant are dangerous to cats."

Ingesting as little as 0.2 per cent of an animal's body weight can result in poisoning, according to the Pet Poison helpline. With treatment, prognosis is fair.

The Purdue University College of Veterinary Medicine states: "These ornamental shrubs aren't commonly nibbled on but they can cause fatal heart problems in dogs, cats and pet birds."

Azaleas, in the same family as rhododendrons, are just as dangerous.

Although beautiful with their delicate trumpet-like blossoms, all parts of these flowers from the seeds to the petalsare extremely toxic to cats and to humans. Ingestion can cause cardiac failure and even death, the Pet Poison Helpline warns.

The plant contains cardiac glycosides such as digitoxin. These naturally occurring poisons affect the heart.

This plant contains ricin, one of the most poisonous naturally occurring substances known. The seeds from the castor bean, ricinus communis, are particularly harmful to cats, the Department of Animal Science at Cornell University warns.

Luckily, the castor bean is not so common in residential gardens and is more commonly found in parks and other outside areas.

Cat owners should consult the comprehensive list of potentially toxic plants put out by the ASPCA Animal Poison Control, Johnson-Bennett told Newsweek.

If you allow your cat outdoors or have cats who come into your yard, check the ASPCA list before planning your garden, she suggests.

"When it comes to having indoor cats, the safest route is to make sure there is no access to any plant," she added. "Even plants not listed as poisonous may still cause gastrointestinal upset if chewed."

See the original post here:
What Plants Are Toxic to Cats? What to Avoid Indoors and in the Garden - Newsweek

For those who are going to be using the east Sinclair interchange (exit 221) on I-80, be prepared for delays this week as crews with McGarvin-Moberly Construction and the Wyoming Department of Transportation begin placing a wearing course on the interchange.

A wearing course helps preserve the structure in addition to providing extra traction. This work will take place on Thursday and Friday, July 8-9, and necessitates the closure of the interchange for about 4-5 hours each morning.

A detour will be in place for motorists needing to use the interchange during each temporary closure.

This work is part of a pavement and bridge rehabilitation project on I-80 east of Sinclair, between mile markers 221-227.5.

The overall project is expected to be complete in early 2022.

To prepare yourself for a potential incident, always keep your vet's phone number handy, along with an after-hours clinic you can call in an emergency. The ASPCA Animal Poison Control Center also has a hotline you can call at (888) 426-4435 for advice.

Even with all of these resources, however, the best cure for food poisoning is preventing it in the first place. To give you an idea of what human foods can be dangerous, Stacker has put together a slideshow of 30 common foods to avoid. Take a look to see if there are any that surprise you.

See the original post here:
Upcoming Work on East Sinclair Interchange - laramielive.com